Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 119, Issue 12, 2012, Pages 1512-1520

  Yu, Y ^a   Hanssen, K F ^b,c   Kalyanaraman, V ^a   Chirindel, A ^a   Jenkins, A J ^a,d   Nankervis, A J ^e   Torjesen, P A ^b   Scholz, H ^c   Henriksen, T ^c   Lorentzen, B ^c   Garg, S K ^f   Menard, M K ^g   Hammad, S M ^h   Scardo, J A ⁱ   Stanley, J R ^j   Wu, M ^a   Basu, A ^k   Aston, C E ^l   Lyons, T J ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ROYAL WOMEN'S HOSPITAL   (Australia)

^f UNIVERSITY OF COLORADO DENVER   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ Gibbs Cancer Center and Research Institute   (United States)

^j Mercy Health Center   (United States)

^k OKLAHOMA STATE UNIVERSITY   (United States)

^l UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Advanced glycation end products; diabetes; hydroimidazolone; N (carboxymethyl)lysine; pre eclampsia; pregnancy; soluble RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; HYDROIMIDAZOLONE; N EPSILON (CARBOXYMETHYL)LYSINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DISEASE DURATION; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; PARITY; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMIDAZOLES; LINEAR MODELS; LYSINE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY IN DIABETICS; PROSPECTIVE STUDIES; RECEPTORS, IMMUNOLOGIC;

EID: 84867581102     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2012.03463.x     Document Type: Article

References (41)

1. Roberts JM, Pearson G, Cutler J, Lindheimer M,. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension 2003; 41: 437-45.
2. Hanson U, Persson B,. Outcome of pregnancies complicated by type 1 insulin-dependent diabetes in Sweden: acute pregnancy complications, neonatal mortality and morbidity. Am J Perinatol 1993; 10: 330-3.
3. Hsu CD, Tan HY, Hong SF, Nickless NA, Copel JA,. Strategies for reducing the frequency of preeclampsia in pregnancies with insulin-dependent diabetes mellitus. Am J Perinatol 1996; 13: 265-8.
4. Yu Y, Jenkins AJ, Nankervis AJ, Hanssen KF, Scholz H, Henriksen T, et al., Anti-angiogenic factors and pre-eclampsia in type 1 diabetic women. Diabetologia 2009; 52: 160-8.
5. Azar M, Basu A, Jenkins AJ, Nankervis AJ, Hanssen KF, Scholz H, et al., Serum carotenoids and fat-soluble vitamins in women with type 1 diabetes and preeclampsia: a longitudinal study. Diabetes Care 2011; 34: 1258-64.
6. Basu A, Alaupovic P, Wu M, Jenkins AJ, Yu Y, Nankervis AJ, et al., Plasma lipoproteins and preeclampsia in women with type 1 diabetes: a prospective study. J Clin Endocrinol Metab 2012; 97: 1752-62.
7. Lyons TJ,. Glycation, carbonyl stress, EAGLEs, and the vascular complications of diabetes. Semin Vasc Med 2002; 2: 175-89.
8. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR,. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996; 271: 9982-6.
9. Kasper M, Schieberle P,. Labeling studies on the formation pathway of Nepsilon-carboxymethyllysine in Maillard-type reactions. Ann N Y Acad Sci 2005; 1043: 59-62.
10. Westwood ME, Argirov OK, Abordo EA, Thornalley PJ,. Methylglyoxal- modified arginine residues-a signal for receptor-mediated endocytosis and degradation of proteins by monocytic THP-1 cells. Biochim Biophys Acta 1997; 1356: 84-94.
11. Karachalias N, Babaei-Jadidi R, Ahmed N, Thornalley PJ,. Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans 2003; 31: 1423-5.
12. Brownlee M,. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
13. Barile GR, Pachydaki SI, Tari SR, Lee SE, Donmoyer CM, Ma W, et al., The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46: 2916-24.
14. Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Yamamoto H,. Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J Pharmacol Sci 2005; 97: 305-11.
15. Kalea AZ, Schmidt AM, Hudson BI,. RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) 2009; 116: 621-37.
16. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al., Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370: 1097-109.
17. Nin JW, Ferreira I, Schalkwijk CG, Prins MH, Chaturvedi N, Fuller JH, et al., Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 2009; 52: 705-14.
18. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, et al., Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes 2010; 59: 2027-32.
19. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, et al., Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 2011; 34: 442-7.
20. Thomas MC, Soderlund J, Lehto M, Makinen VP, Moran JL, Cooper ME, et al., Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia 2011; 54: 2669-77.
21. Redman CW, Sargent IL,. Latest advances in understanding preeclampsia. Science 2005; 308: 1592-4.
22. Ness RB, Roberts JM,. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996; 175: 1365-70.
23. Cooke CL, Brockelsby JC, Baker PN, Davidge ST,. The receptor for advanced glycation end products (RAGE) is elevated in women with preeclampsia. Hypertens Pregnancy 2003; 22: 173-84.
24. Chekir C, Nakatsuka M, Noguchi S, Konishi H, Kamada Y, Sasaki A, et al., Accumulation of advanced glycation end products in women with preeclampsia: possible involvement of placental oxidative and nitrative stress. Placenta 2006; 27: 225-33.
25. Fasshauer M, Seeger J, Waldeyer T, Schrey S, Ebert T, Lossner U, et al., Endogenous soluble receptor for advanced glycation endproducts is increased in preeclampsia. J Hypertens 2008; 26: 1824-8.
26. Oliver EA, Buhimschi CS, Dulay AT, Baumbusch MA, Abdel-Razeq SS, Lee SY, et al., Activation of the receptor for advanced glycation end products system in women with severe preeclampsia. J Clin Endocrinol Metab 2011; 96: 689-98.
27. Kwon JH, Kim YH, Kwon JY, Park YW,. Clinical significance of serum sRAGE and esRAGE in women with normal pregnancy and preeclampsia. J Perinat Med 2011; 39: 507-13.
28. Germanova A, Koucky M, Hajek Z, Parizek A, Zima T, Kalousova M,. Soluble receptor for advanced glycation end products in physiological and pathological pregnancy. Clin Biochem 2010; 43: 442-6.
29. Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Birkeland KI, et al., High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol 2005; 25: 815-20.
30. Kilhovd BK, Giardino I, Torjesen PA, Birkeland KI, Berg TJ, Thornalley PJ, et al., Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 2003; 52: 163-7.
31. Berg TJ, Clausen JT, Torjesen PA, Dahl-Jorgensen K, Bangstad HJ, Hanssen KF,. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care 1998; 21: 1997-2002.
32. Makita Z, Vlassara H, Cerami A, Bucala R,. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992; 267: 5133-8.
33. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, et al., Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 2009; 204: 288-92.
34. Myint KM, Yamamoto Y, Sakurai S, Harashima A, Watanabe T, Li H, et al., Blockade of diabetic vascular injury by controlling of AGE-RAGE system. Curr Drug Targets 2005; 6: 447-52.
35. Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone S, et al., Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes 2011; 60: 2379-85.
36. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, et al., Identification, classification, and expression of RAGE gene splice variants. FASEB J 2008; 22: 1572-80.
37. Pertyńska-Marczewska M, Glowacka E, Sobczak M, Cypryk K, Wilczynski J,. Glycation endproducts, soluble receptor for advanced glycation endproducts and cytokines in diabetic and non-diabetic pregnancies. Am J Reprod Immunol 2009; 61: 175-82.
38. Tsukahara H, Ohta N, Sato S, Hiraoka M, Shukunami K, Uchiyama M, et al., Concentrations of pentosidine, an advanced glycation end-product, in umbilical cord blood. Free Radic Res 2004; 38: 691-5.
39. Blaauw J, Smit AJ, van Pampus MG, van Doormaal JJ, Aarnoudse JG, Rakhorst G, et al., Skin autofluorescence, a marker of advanced glycation end products and oxidative stress, is increased in recently preeclamptic women. Am J Obstet Gynecol 2006; 195: 717-22.
40. Harsem NK, Braekke K, Torjussen T, Hanssen K, Staff AC,. Advanced glycation end products in pregnancies complicated with diabetes mellitus or preeclampsia. Hypertens Pregnancy 2008; 27: 374-86.
41. Bierhaus A, Nawroth PP,. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009; 52: 2251-63.